Outpatient Oncology Infusion Market to Reach USD 7.0 Billion by 2035 | Growing at a CAGR of 10.4% | North America Leads, Asia Pacific Fastest-Growing | Key Players - InfuSystem, Baxter, Becton Dickinson, ICU Medical, B. Braun SE

Leander, Texas and Tokyo, Japan - Jan.29.2026
As per DataM Intelligence research report "Outpatient Oncology Infusion Market size reached USD 2.6 billion in 2025 and is expected to reach USD 3.1 billion by 2026 to 7 billion in 2035, growing with a CAGR of 10.4% during the forecast period 2025-2035"

The market is driven by advancements in cancer infusion therapies, rising prevalence of cancer globally, shift toward outpatient and home-based care for cost-effectiveness and patient convenience, FDA approvals for new targeted therapies and immunotherapies, and increasing adoption of portable infusion devices. Despite challenges like reimbursement issues, regulatory compliance, lack of skilled professionals, and patient safety concerns, demand remains strong due to preference for non-hospital settings and expanding oncology infrastructure.

Download your exclusive sample report today: (corporate email gets priority access):
https://www.datamintelligence.com/download-sample/outpatient-oncology-infusion-market?sindhuri
(Single User Report: USD 4350 & One Year Database Subscription: USD 12K)

Outpatient Oncology Infusion Market: Competitive Intelligence
InfuSystem, Intera Oncology, Intuvie LLC, Baxter, Delta Med, Becton, Dickinson and Company, ICU Medical, Micrel Medical Devices SA, Viltechmeda, B. Braun SE
The Outpatient Oncology Infusion Market continues to gain structural strength through the combined influence of InfuSystem, Intera Oncology, Intuvie LLC, Baxter, Delta Med, Becton, Dickinson and Company, ICU Medical, Micrel Medical Devices SA, Viltechmeda, and B. Braun SE. Together, these companies support critical oncology care in outpatient settings, where accurate dosing, patient safety, portability, and compatibility with chemotherapy, immunotherapy, and targeted therapies remain essential. Their portfolios address demanding requirements including precise infusion control, reduced infection risks, and support for home or clinic-based administration across various cancer types. As a result, the Outpatient Oncology Infusion Market benefits from steady demand, technological advancements in pumps and accessories, and broad relevance in cancer treatment despite regulatory and reimbursement hurdles.
The collective momentum created by these companies enhances the competitive depth of the Outpatient Oncology Infusion Market by combining specialized device innovation with global distribution and clinical partnerships. Companies like Becton, Dickinson and Company, Baxter, B. Braun SE, and ICU Medical bring extensive manufacturing scale, regulatory expertise, and focus on safety features. At the same time, InfuSystem, Intera Oncology, and Micrel Medical Devices SA contribute application-specific solutions, particularly in ambulatory pumps and oncology-focused services. This balance of scale, innovation, and service reach supports consistent product availability and adaptation to evolving cancer treatment protocols and patient preferences.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/outpatient-oncology-infusion-market?sindhuri
(Single User Report: USD 4350 & One Year Database Subscription: USD 12K)

Product Launches & Partnerships
✅ March 2022 - Shanghai MicroPort Lifesciences Co., Ltd. (China)
Shanghai MicroPort Lifesciences received marketing approval from China's NMPA for its AutoEx Chemotherapy Infusion Pump, enhancing options for outpatient chemotherapy delivery.
✅ February 2022 - InfuSystem Holdings, Inc. (United States)
InfuSystem Holdings agreed with American Oncology Network, LLC (effective January 1, 2022) to provide ambulatory infusion pumps and related services to support outpatient oncology care.

Segment Covered in the Outpatient Oncology Infusion Market:
By Product
The market is segmented into Infusion Pumps ~35%, Intravenous (IV) Sets ~30%, IV Cannulas ~20%, and Needleless Connectors ~15%, with infusion pumps and IV sets dominating due to their critical role in accurate, controlled drug delivery in outpatient oncology settings. Needleless connectors and cannulas gain steady adoption driven by infection control requirements, patient safety initiatives, and high outpatient procedure volumes.
By Therapy
Therapies include Chemotherapy ~45%, Immunotherapy ~25%, Targeted Therapy ~20%, Hormone Therapy ~5%, and Others ~5%, with chemotherapy leading due to its continued use across a wide range of cancer indications. Immunotherapy and targeted therapy segments show strong growth supported by advances in biologics, precision medicine, and improved patient outcomes in outpatient care models.
By Cancer Type
Cancer types comprise Solid Tumors ~70% and Hematologic Malignancies ~30%, with solid tumors dominating due to higher incidence rates and extensive use of outpatient infusion for breast, lung, colorectal, and prostate cancers. Hematologic malignancies maintain steady demand driven by ongoing treatment regimens for leukemia, lymphoma, and multiple myeloma.

Buy Now & Unlock 360° Market Intelligence:
https://www.datamintelligence.com/buy-now-page?report=outpatient-oncology-infusion-market&sindhuri
(Single User Report: USD 4350 & One Year Database Subscription: USD 12K)

Regional Analysis
North America - ~41.3% Share (Largest)
North America holds the largest share (approximately 41.3% in 2022) due to high cancer prevalence, strong partnerships, FDA clearances, advanced healthcare infrastructure, and presence of key players in the U.S. and Canada.
Europe
Europe supports growth through established oncology networks, regulatory support, and adoption in countries like Germany and the UK.
Asia Pacific - Fastest-Growing
Asia Pacific is the fastest-growing region driven by rising cancer incidence, improving healthcare access, and increasing outpatient facilities in China, India, and Japan.
Latin America
Latin America shows emerging growth in oncology infrastructure and access to infusion therapies.
Middle East & Africa
Middle East & Africa expands with investments in cancer care and outpatient services in select countries.

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?sindhuri
✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.